vs
Side-by-side financial comparison of Paycom (PAYC) and Prestige Consumer Healthcare Inc. (PBH). Click either name above to swap in a different company.
Paycom is the larger business by last-quarter revenue ($544.3M vs $283.4M, roughly 1.9× Prestige Consumer Healthcare Inc.). Paycom runs the higher net margin — 20.9% vs 16.5%, a 4.4% gap on every dollar of revenue. On growth, Paycom posted the faster year-over-year revenue change (10.2% vs -2.4%). Paycom produced more free cash flow last quarter ($122.6M vs $75.3M). Over the past eight quarters, Paycom's revenue compounded faster (4.3% CAGR vs 1.2%).
Paycom Software, Inc., known simply as Paycom, is an online payroll and human resource software provider based in Oklahoma City, Oklahoma with offices throughout the United States. It is attributed with being one of the first fully online payroll providers. Founded in 1998, it reported annual revenue of $2.052 billion for 2025, up from $1.883 billion for 2024.
Prestige Consumer Healthcare Inc. is an American company that markets and distributes over-the-counter healthcare and household cleaning products. It was formed by the merger of Medtech Products, Inc., Prestige Brands International, and the Spic and Span Company in 1996. The company is headquartered in Tarrytown, New York and operates a manufacturing facility in Lynchburg, Virginia.
PAYC vs PBH — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $544.3M | $283.4M |
| Net Profit | $113.8M | $46.7M |
| Gross Margin | 83.9% | 55.5% |
| Operating Margin | 28.9% | 29.1% |
| Net Margin | 20.9% | 16.5% |
| Revenue YoY | 10.2% | -2.4% |
| Net Profit YoY | 0.2% | -23.5% |
| EPS (diluted) | $2.06 | $0.97 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $544.3M | $283.4M | ||
| Q3 25 | $493.3M | $274.1M | ||
| Q2 25 | $483.6M | $249.5M | ||
| Q1 25 | $530.5M | $296.5M | ||
| Q4 24 | $493.9M | $290.3M | ||
| Q3 24 | $451.9M | $283.8M | ||
| Q2 24 | $437.5M | $267.1M | ||
| Q1 24 | $499.9M | $277.0M |
| Q4 25 | $113.8M | $46.7M | ||
| Q3 25 | $110.7M | $42.2M | ||
| Q2 25 | $89.5M | $47.5M | ||
| Q1 25 | $139.4M | $50.1M | ||
| Q4 24 | $113.6M | $61.0M | ||
| Q3 24 | $73.3M | $54.4M | ||
| Q2 24 | $68.0M | $49.1M | ||
| Q1 24 | $247.2M | $49.5M |
| Q4 25 | 83.9% | 55.5% | ||
| Q3 25 | 82.7% | 55.3% | ||
| Q2 25 | 81.9% | 56.2% | ||
| Q1 25 | 84.1% | 57.3% | ||
| Q4 24 | 83.1% | 55.5% | ||
| Q3 24 | 80.5% | 55.5% | ||
| Q2 24 | 80.8% | 54.7% | ||
| Q1 24 | 84.3% | 54.8% |
| Q4 25 | 28.9% | 29.1% | ||
| Q3 25 | 22.8% | 29.1% | ||
| Q2 25 | 23.2% | 28.8% | ||
| Q1 25 | 34.9% | 29.8% | ||
| Q4 24 | 30.1% | 31.7% | ||
| Q3 24 | 23.2% | 29.7% | ||
| Q2 24 | 21.7% | 27.0% | ||
| Q1 24 | 57.2% | 29.7% |
| Q4 25 | 20.9% | 16.5% | ||
| Q3 25 | 22.4% | 15.4% | ||
| Q2 25 | 18.5% | 19.0% | ||
| Q1 25 | 26.3% | 16.9% | ||
| Q4 24 | 23.0% | 21.0% | ||
| Q3 24 | 16.2% | 19.2% | ||
| Q2 24 | 15.5% | 18.4% | ||
| Q1 24 | 49.4% | 17.9% |
| Q4 25 | $2.06 | $0.97 | ||
| Q3 25 | $1.96 | $0.86 | ||
| Q2 25 | $1.58 | $0.95 | ||
| Q1 25 | $2.48 | $1.00 | ||
| Q4 24 | $2.04 | $1.22 | ||
| Q3 24 | $1.31 | $1.09 | ||
| Q2 24 | $1.20 | $0.98 | ||
| Q1 24 | $4.37 | $0.98 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $370.0M | $62.4M |
| Total DebtLower is stronger | — | $1.0B |
| Stockholders' EquityBook value | $1.7B | $1.8B |
| Total Assets | $7.6B | $3.5B |
| Debt / EquityLower = less leverage | — | 0.56× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $370.0M | $62.4M | ||
| Q3 25 | $375.0M | $119.1M | ||
| Q2 25 | $532.2M | $139.5M | ||
| Q1 25 | $520.8M | $97.9M | ||
| Q4 24 | $402.0M | $50.9M | ||
| Q3 24 | $325.8M | $51.5M | ||
| Q2 24 | $346.5M | $34.3M | ||
| Q1 24 | $371.3M | $46.5M |
| Q4 25 | — | $1.0B | ||
| Q3 25 | — | $993.1M | ||
| Q2 25 | — | $992.7M | ||
| Q1 25 | — | $992.4M | ||
| Q4 24 | — | $992.0M | ||
| Q3 24 | — | $1.1B | ||
| Q2 24 | — | $1.1B | ||
| Q1 24 | — | $1.1B |
| Q4 25 | $1.7B | $1.8B | ||
| Q3 25 | $1.7B | $1.8B | ||
| Q2 25 | $1.8B | $1.9B | ||
| Q1 25 | $1.7B | $1.8B | ||
| Q4 24 | $1.6B | $1.8B | ||
| Q3 24 | $1.5B | $1.7B | ||
| Q2 24 | $1.4B | $1.7B | ||
| Q1 24 | $1.4B | $1.7B |
| Q4 25 | $7.6B | $3.5B | ||
| Q3 25 | $4.2B | $3.4B | ||
| Q2 25 | $4.0B | $3.4B | ||
| Q1 25 | $4.6B | $3.4B | ||
| Q4 24 | $5.9B | $3.3B | ||
| Q3 24 | $3.5B | $3.3B | ||
| Q2 24 | $4.3B | $3.3B | ||
| Q1 24 | $4.7B | $3.3B |
| Q4 25 | — | 0.56× | ||
| Q3 25 | — | 0.54× | ||
| Q2 25 | — | 0.54× | ||
| Q1 25 | — | 0.54× | ||
| Q4 24 | — | 0.55× | ||
| Q3 24 | — | 0.61× | ||
| Q2 24 | — | 0.65× | ||
| Q1 24 | — | 0.68× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $196.1M | $78.3M |
| Free Cash FlowOCF − Capex | $122.6M | $75.3M |
| FCF MarginFCF / Revenue | 22.5% | 26.6% |
| Capex IntensityCapex / Revenue | 13.5% | 1.1% |
| Cash ConversionOCF / Net Profit | 1.72× | 1.68× |
| TTM Free Cash FlowTrailing 4 quarters | $408.0M | $267.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $196.1M | $78.3M | ||
| Q3 25 | $177.8M | $57.5M | ||
| Q2 25 | $122.5M | $79.0M | ||
| Q1 25 | $182.5M | $61.8M | ||
| Q4 24 | $160.4M | $65.1M | ||
| Q3 24 | $92.8M | $69.8M | ||
| Q2 24 | $132.1M | $54.8M | ||
| Q1 24 | $148.6M | $66.9M |
| Q4 25 | $122.6M | $75.3M | ||
| Q3 25 | $79.8M | $55.4M | ||
| Q2 25 | $60.8M | $78.2M | ||
| Q1 25 | $144.8M | $58.4M | ||
| Q4 24 | $109.0M | $63.5M | ||
| Q3 24 | $44.6M | $67.8M | ||
| Q2 24 | $86.5M | $53.6M | ||
| Q1 24 | $100.9M | $63.8M |
| Q4 25 | 22.5% | 26.6% | ||
| Q3 25 | 16.2% | 20.2% | ||
| Q2 25 | 12.6% | 31.3% | ||
| Q1 25 | 27.3% | 19.7% | ||
| Q4 24 | 22.1% | 21.9% | ||
| Q3 24 | 9.9% | 23.9% | ||
| Q2 24 | 19.8% | 20.1% | ||
| Q1 24 | 20.2% | 23.0% |
| Q4 25 | 13.5% | 1.1% | ||
| Q3 25 | 19.9% | 0.8% | ||
| Q2 25 | 12.8% | 0.3% | ||
| Q1 25 | 7.1% | 1.2% | ||
| Q4 24 | 10.4% | 0.5% | ||
| Q3 24 | 10.7% | 0.7% | ||
| Q2 24 | 10.4% | 0.4% | ||
| Q1 24 | 9.5% | 1.1% |
| Q4 25 | 1.72× | 1.68× | ||
| Q3 25 | 1.61× | 1.36× | ||
| Q2 25 | 1.37× | 1.66× | ||
| Q1 25 | 1.31× | 1.23× | ||
| Q4 24 | 1.41× | 1.07× | ||
| Q3 24 | 1.27× | 1.28× | ||
| Q2 24 | 1.94× | 1.12× | ||
| Q1 24 | 0.60× | 1.35× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PAYC
| Recurring | $510.3M | 94% |
| Interest On Funds Held For Clients | $27.2M | 5% |
| Implementation And Other | $6.8M | 1% |
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
